Interchangeability, early meetings, review timelines and access are among the key priorities that have been set out by US biosimilars industry stakeholders as the Biosimilar User Fee Act approaches its second reauthorization.
As the US Food and Drug Administration aims to set priorities for the reauthorization of BsUFA for fiscal years 2023...






